WO2003076602A3 - Siomerieux s.a. - inserm - Google Patents

Siomerieux s.a. - inserm Download PDF

Info

Publication number
WO2003076602A3
WO2003076602A3 PCT/FR2003/000741 FR0300741W WO03076602A3 WO 2003076602 A3 WO2003076602 A3 WO 2003076602A3 FR 0300741 W FR0300741 W FR 0300741W WO 03076602 A3 WO03076602 A3 WO 03076602A3
Authority
WO
WIPO (PCT)
Prior art keywords
monocytes
mature
differentiation
vivo
lysophosphatidycholine
Prior art date
Application number
PCT/FR2003/000741
Other languages
English (en)
Other versions
WO2003076602A2 (fr
Inventor
Vincent Lotteau
Patrice Andre
Original Assignee
Biomerieux Sa
Inst Nat Sante Rech Med
Vincent Lotteau
Patrice Andre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0203499A external-priority patent/FR2836828A1/fr
Application filed by Biomerieux Sa, Inst Nat Sante Rech Med, Vincent Lotteau, Patrice Andre filed Critical Biomerieux Sa
Priority to EP03725275A priority Critical patent/EP1483374B1/fr
Priority to US10/503,402 priority patent/US7368287B2/en
Priority to DE60305167T priority patent/DE60305167T2/de
Priority to JP2003574809A priority patent/JP4482683B2/ja
Priority to AU2003227822A priority patent/AU2003227822A1/en
Publication of WO2003076602A2 publication Critical patent/WO2003076602A2/fr
Publication of WO2003076602A3 publication Critical patent/WO2003076602A3/fr
Priority to US12/076,591 priority patent/US20080176820A1/en
Priority to US12/929,701 priority patent/US20110135684A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La présente invention concerne un procédé pour la différenciation in vitro de monocytes en cellules dendritriques matures selon lequel A. on dispose de monocytes dans un milieu de culture approprié, B. on induit la différenciation des monocytes en cellules dendritiques en présence d'un facteur de différentiation, C. on additionne audit milieu de L-a-lysophosphatidylcholine et on obtient des cellules dendritiques matures. L'invention concerne également l'utilisation d'au moins un inhibiteur de L-a-lysophosphatidylcholine pour la fabrication d'un médicament pour la prévention d'une inflammation et/ou pour lutter contre une maladie inflammatoire et/ou une maladie autoimmune.
PCT/FR2003/000741 2002-03-11 2003-03-07 Siomerieux s.a. - inserm WO2003076602A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP03725275A EP1483374B1 (fr) 2002-03-11 2003-03-07 Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
US10/503,402 US7368287B2 (en) 2002-03-11 2003-03-07 Use of L-α-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro
DE60305167T DE60305167T2 (de) 2002-03-11 2003-03-07 Verwendung von l-alpha lysophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritischen zellen
JP2003574809A JP4482683B2 (ja) 2002-03-11 2003-03-07 ｉｎｖｉｔｒｏで単球を成熟樹状細胞に分化させるためのＬ−α−リゾホスファチジルコリンの使用
AU2003227822A AU2003227822A1 (en) 2002-03-11 2003-03-07 Use of l-$g(a)-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vivo
US12/076,591 US20080176820A1 (en) 2002-03-11 2008-03-20 Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro
US12/929,701 US20110135684A1 (en) 2002-03-11 2011-02-09 Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vitro

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR02/03499 2002-03-11
FR0203499A FR2836828A1 (fr) 2002-03-11 2002-03-11 Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
FR0301063A FR2836829B1 (fr) 2002-03-11 2003-01-30 Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
FR03/01063 2003-01-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/076,591 Division US20080176820A1 (en) 2002-03-11 2008-03-20 Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro
US12/076,591 Continuation US20080176820A1 (en) 2002-03-11 2008-03-20 Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro

Publications (2)

Publication Number Publication Date
WO2003076602A2 WO2003076602A2 (fr) 2003-09-18
WO2003076602A3 true WO2003076602A3 (fr) 2004-04-08

Family

ID=27767084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000741 WO2003076602A2 (fr) 2002-03-11 2003-03-07 Siomerieux s.a. - inserm

Country Status (9)

Country Link
US (3) US7368287B2 (fr)
EP (2) EP1483374B1 (fr)
JP (1) JP4482683B2 (fr)
AT (1) ATE325866T1 (fr)
AU (1) AU2003227822A1 (fr)
DE (1) DE60305167T2 (fr)
ES (1) ES2262994T3 (fr)
FR (1) FR2836829B1 (fr)
WO (1) WO2003076602A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
ES2806751T3 (es) * 2013-09-26 2021-02-18 Nat Univ Singapore Composiciones y métodos utilizando andamios de lisofosfatidilcolina
EP3000471A1 (fr) * 2014-09-28 2016-03-30 Bernhard-Nocht-Institut für Tropenmedizin Nouvelles molécules immunostimulantes
EP3357512A4 (fr) * 2015-09-29 2019-05-29 Osaka University Promoteur de l'infiltration de leucocytes et immuno-activateur des tumeurs
KR101862502B1 (ko) * 2017-01-02 2018-05-29 성균관대학교산학협력단 재구성 인공 암세포, 이의 제조 방법, 및 이를 포함하는 항암 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746652A (en) * 1986-11-18 1988-05-24 Wake Forest University Method of inducing diuresis with lysophospholipids
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
WO1998057631A1 (fr) * 1997-06-18 1998-12-23 The General Hospital Corporation UTILISATION D'AGONISTES DE PPARη POUR INHIBER LA PRODUCTION DE CYTOKINE INFLAMMATOIRE
WO2003006634A2 (fr) * 2001-07-09 2003-01-23 Biomerieux Utilisation de lipoproteines oxydees pour obtenir la differenciation de cellules precurseur en cellules dendritiques matures

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
CA2090738C (fr) * 1993-02-24 1996-05-21 Hema-Quebec Utilisation du paf
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746652A (en) * 1986-11-18 1988-05-24 Wake Forest University Method of inducing diuresis with lysophospholipids
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
WO1998057631A1 (fr) * 1997-06-18 1998-12-23 The General Hospital Corporation UTILISATION D'AGONISTES DE PPARη POUR INHIBER LA PRODUCTION DE CYTOKINE INFLAMMATOIRE
WO2003006634A2 (fr) * 2001-07-09 2003-01-23 Biomerieux Utilisation de lipoproteines oxydees pour obtenir la differenciation de cellules precurseur en cellules dendritiques matures

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BEALES P E ET AL: "Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 357, no. 2-3, 18 September 1998 (1998-09-18), pages 221 - 225, XP000978448, ISSN: 0014-2999 *
CARSON M J & LO D: "The push-me pull-you of T cell activation.", SCIENCE, vol. 293, no. 5530, 27 July 2001 (2001-07-27), pages 618 - 619, XP002227668, ISSN: 0036-8075 *
COUTANT F ET AL: "Mature dendritic cell generation promoted by lysophosphatidylcholine.", JOURNAL OF IMMUNOLOGY, vol. 169, no. 4, 15 August 2002 (2002-08-15), pages 1688 - 1695, XP002227670, ISSN: 0022-1767 *
DICHMANN S ET AL: "Downregulation of platelet-activating factor responsiveness during maturation of human dendritic cells.", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 185, no. 3, December 2000 (2000-12-01), pages 394 - 400, XP008012539, ISSN: 0021-9541 *
GRANATO D ET AL: "Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro.", JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, vol. 24, no. 2, March 2000 (2000-03-01), pages 113 - 118, XP008022928, ISSN: 0148-6071 *
KABAROWSKI J H S ET AL: "Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A.", SCIENCE, vol. 293, no. 5530, 27 July 2001 (2001-07-27), pages 702 - 705, XP002227669, ISSN: 0036-8075 *
NIINO M ET AL: "Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma.", JOURNAL OF NEUROIMMUNOLOGY, vol. 116, no. 1, 1 May 2001 (2001-05-01), pages 40 - 48, XP002256645, ISSN: 0165-5728 *
PERRIN-COCON L ET AL: "Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte", JOURNAL OF IMMUNOLOGY, vol. 167, no. 7, 1 October 2001 (2001-10-01), pages 3785 - 3791, XP002196476, ISSN: 0022-1767 *
SOZZANI S ET AL: "Human monocyte-derived and CD34+ cell-derived dendritic cells express functional receptors for platelet activating factor.", FEBS LETTERS, vol. 418, no. 1-2, 24 November 1997 (1997-11-24), pages 98 - 100, XP002227667, ISSN: 0014-5793 *
WANTEN G J ET AL: "Influence of structurally different lipid emulsions on human neutrophil oxygen radical production.", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 29, no. 4, April 1999 (1999-04-01), pages 357 - 363, XP002256644, ISSN: 0014-2972 *
WEBER C ET AL: "Enhancement of monocyte adhesion to endothelial cells by oxidatively modified low-density lipoprotein is mediated by activation of CD11b.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 206, no. 2, 17 January 1995 (1995-01-17), pages 621 - 628, XP002227666, ISSN: 0006-291X *

Also Published As

Publication number Publication date
EP1666039A1 (fr) 2006-06-07
ATE325866T1 (de) 2006-06-15
EP1483374B1 (fr) 2006-05-10
JP4482683B2 (ja) 2010-06-16
DE60305167D1 (de) 2006-06-14
DE60305167T2 (de) 2007-05-31
US20050054095A1 (en) 2005-03-10
AU2003227822A1 (en) 2003-09-22
JP2005530488A (ja) 2005-10-13
WO2003076602A2 (fr) 2003-09-18
AU2003227822A8 (en) 2003-09-22
US20080176820A1 (en) 2008-07-24
US7368287B2 (en) 2008-05-06
US20110135684A1 (en) 2011-06-09
FR2836829B1 (fr) 2005-11-25
ES2262994T3 (es) 2006-12-01
EP1483374A2 (fr) 2004-12-08
FR2836829A1 (fr) 2003-09-12

Similar Documents

Publication Publication Date Title
AU2001282123A1 (en) Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells
WO2003096972A3 (fr) Angiogenese et mise au point de tissu cardiaque utilisant des hydrogels peptidiques, compositions apparentees et procedes d'utilisation
WO2001064046A3 (fr) Procede d'isolation de collagene d'eponges ainsi que production de collagene nanoparticulaire et son utilisation
AU2003253217A1 (en) Composition for heart disease, method to prepare same and uses thereof
WO2003020889A3 (fr) Procedes de maturation de cellules dendritiques plasmocytoides au moyen de molecules modifiant les reponses immunitaires
AU2001263217A1 (en) Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids
WO2004080175A3 (fr) Echafaudage pour croissance et differenciation cellulaires
AU2002366532A1 (en) In vitro production of dendritic cells from cd14+ monocytes
WO2004025270A3 (fr) Methodes permettant de mesurer les taux de transport inverse du cholesterol in vivo utilises comme indice d'anti-atherogenicite
WO2003024308A3 (fr) Procedes permettant d'analyser le facteur de croissance du tissu conjonctif
WO2003046161A3 (fr) Procede d'expansion et de differenciation ex vivo de cellules souches multipotentes
AU2003212245A1 (en) Method of diagnosis of inflammatory diseases using calgranulin c
WO2003076602A3 (fr) Siomerieux s.a. - inserm
AU2003202470A1 (en) Process for producing 6,6,6-trifluoro-3,5-dioxohexanoic acid ester and tautomer thereof
WO2007015175A3 (fr) Utilisation d'inhibiteurs de pp-1 pour eviter des problemes d'epissage
WO2005052140A3 (fr) Cellules souches somatiques multipotentes d'un ligament periodontique d'un etre humain et leurs utilisations
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2001066119A3 (fr) Compositions pharmaceutiques comprenant des alginates
WO2005030927A3 (fr) Procedes et compositions pour le controle de l'inflammation in vivo
AU2003237150A1 (en) Compositions and methods for treating inflammatory connective tissue diseases
WO2002036096A8 (fr) Produits viscoelastiques transitionnels ne necessitant pas d'aspiration destines a la chirurgie
AU2001256998A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2001078720A8 (fr) Abaissement du niveau intracellulaire de beta-catenine par administration d'hydroxymatairesinol
WO2002059281A3 (fr) Production elevee de cytokine a viabilite cellulaire amelioree

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003725275

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038053969

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003574809

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10503402

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003725275

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003725275

Country of ref document: EP